NICE: appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine

NICE | February 2020 | Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine

NICE has recently  published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.

Full details from NICE

NICE Neutropenic sepsis: prevention and management in people with cancer

NICE | February 2020 | Neutropenic sepsis: prevention and management in people with cancer

NICE has published its surveillance decision on Neutropenic sepsis: prevention and management in people with cancer;  NICE will not update its  guideline on neutropenic sepsis.

NICE will amend recommendation 1.2.1.1 about fluoroquinolones for prophylaxis of neutropenic sepsis to add a link to the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update on fluoroquinolone antibiotics.

Full details available from NICE

 

Nasal spray medicine for treatment-resistant depression not recommended by NICE

NICE | January 2020 | Nasal spray medicine for treatment-resistant depression not recommended by NICE

A nasal spray for treatment-resistant depression has not been recommended by NICE because of uncertainties over its clinical and cost effectiveness.

human-3269822_640

Esketamine (also called Spravato and made by Janssen) with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) is not recommended, within its marketing authorisation, for adults with treatment-resistant depression that has not responded to at least two different antidepressants in the current moderate to severe depressive episode (Source: NICE).

Full details from NICE 

Nasal spray medicine for treatment-resistant depression not recommended by NICE

[NICE] Behaviour change: digital and mobile health interventions

NICE |  January  2019 | Behaviour change: digital and mobile health interventions